A me-too strategy for me-too drugs

December 31st, 2008 by David E. Williams of the Health business blog

AstraZeneca appears set to follow Merck into the market for “bio-similars.” (See AstraZeneca may join generic rush.) Congress and the media tend to portray biosimilars are analogous to generic chemistry-based pharmaceuticals, and therefore believe that they will lead to much lower prices as a result of the commoditization of these products. If all goes according to plan, that should cut the price of biologics by 50 to 95 percent as has been the case for generic versions of traditional pharmaceuticals.

Pharma and biotech companies aren’t seeing it this way and neither am I. Although they won’t say so, pharma companies are starting to realize that biosimilars –which unlike traditional generics cannot be subsituted by a pharmacist for a branded product– are really like me-too products within a class of drugs. That’s exactly the model that’s enabled multiple blockbusters within a given class in the mainstream pharma business, and led to higher spending overall. Biosimilars are unlikely to be a lot cheaper than the products they copy, and they will have all the sales and marketing costs associated with a branded product, plus some of the development costs. Don’t be surprised if some biosimilars are actually priced higher than the original products, based on some real or perceived improvement in efficacy or safety. That’s what happened when me-too drugs like Lipitor entered the statin market. (See Generic biologics — or Me Too Drugs 2.0? for more details.)

AstraZeneca won’t be the last company to pursue this strategy. If a regulatory pathway for bio-similars is established in the US, every big pharma will jump on the bandwagon.

If policymakers want to control the cost of biologics, there’s a much simpler and easier way. Simply regulate the price of biologics once their patents expire. That would have several advantages:

  • Guaranteed lower pricing and certainty about when lower pricing will be available
  • No need to subject patients to the hazards of clinical trials
  • No need for FDA to stretch itself further monitoring new biologics manufacturing facilities –which are notoriously difficult to run well

It wouldn’t even be that bad for biologics companies. They’d already have earned their profits during the patented life of the product, and would retain 100 percent market share post-patent expiration. They can’t really complain about the government interfering with the free market, considering that patents are granted by the government in the first place.

The only real losers in this plan would be generic biologics companies. Since the industry doesn’t even really exist yet, now is a good time to implement my scheme.


Posted in Economics, Pharma, Policy and politics | 2 Comments »

Cavalcade of Risk is up at Colorado Health Insurance Insider

December 31st, 2008 by David E. Williams of the Health business blog

Check out the latest Cavalcade of Risk at Colorado Health Insurance Insider.


Posted in Announcements, Blogs | No Comments »

(Un)acceptable quality levels in health care

December 30th, 2008 by David E. Williams of the Health business blog

In the bad old days of American manufacturing aka the 1970s, terms like  “acceptable quality level” were widely used. The idea was that defects and errors were inevitable and that customers expected them. Only later did concepts such as six sigma emerge, reflecting the radical idea that defects can be extremely rare, i.e., a few per million.

Unfortunately health care delivery is still in the defects per thousand or even defects per hundred mode. Some errors are trivial and almost laughable. Others are deadly and inexcusable. Here are three examples I heard about within the last 24 hours, in escalating order of concern.
Last night a friend told me the story of his nine year old, who hurt her pinkie. He took his daughter to the emergency room of a local, highly-regarded hospital, where she was x-rayed and told there was a hairline fracture at the tip. Discharge instructions were unclear, but a few days later he brought her to a hand surgeon at the same hospital. Despite the hospital’s multi-million dollar EHR and PACS system the hand surgeon could not retrieve the original x-ray. (The dad is an MIT grad and told me he had actually made a point of taking his daughter to the same hospital because he assumed the doc would have access to the image.) A new x-ray was ordered, but was inconclusive. Through palpation, the surgeon concluded there was a fracture on the growth plate. In any case the treatment recommendation was the same. But wouldn’t it have been nice for the hand surgeon to have seen the original x-ray and for the patient to have avoided an extra zap of radiation, however small? Of course there’s the duplication of expense, too…

Overhearing this story, an acquaintance told us about his recent experience. He had what he described as a bad stomach ache that didn’t go away over a period of days. He called his internist at a world-renowned hospital here in Boston, and left several voicemails over the course of almost a week. At one point he managed to speak to a physician on call, who told him to go to the emergency room. He went and found out he had appendicitis. After he recovered and visited his internist, the internist asked, “Why didn’t you call me?” The patient was flabbergasted, and told the doc he could tell him exactly what his outgoing voicemail message says since he’d heard it so many times.

Finally, on MedPage Today I read High Error Rates Found with Outpatient Cancer Therapy, which really concerns me:

Drug-related errors occurred in 7.1% of adult visits (95% CI 5.7% to 8.6%) and 18.8% of pediatric visits (95% CI 12.5% to 26.9%), according to a review of nearly 1,400 visits at four geographically diverse outpatient clinics, reported Kathleen E. Walsh, M.D., M.Sc., of the University of Massachusetts, and colleagues.

Of the 112 errors identified, 64 had “potential to cause injury,” the researchers said online in the Journal of Clinical Oncology. Actual injury occurred in 15 cases, they added…

Per 1,000 medication orders, the researchers counted 8.2 errors associated with adult visits (95% CI 6.5 to 9.9) and 24.1 errors for pediatric patients (95% CI 14.2 to 34.1).

The higher rate of pediatric errors in the current study was also reflected in potentially injurious errors and for those actually causing harm.

Dr. Walsh and colleagues found rates of 9.9 potentially injurious errors per 1,000 medication orders for pediatric patients, versus 5.0 per 1,000 orders in adults.

For actual injuries, the rates were 4.3 per 1,000 orders in children and 1.0 per 1,000 orders in adults (P values not reported)…

Dr. Walsh and colleagues said their estimates were probably conservative. They said that direct observation of drug administration and interviews with patients and providers would likely have revealed additional errors not picked up by the chart reviews.

A lot of the errors are made by adults self-administering the drugs inappropriately or parents administering drugs inappropriately to their kids. This could be corrected by better communication and training.

It’s pretty shocking that people struggling with cancer end up as the victim of so many errors in their treatment. McDonald’s would be out of business if they screwed up so many orders. So would Fedex. American consumers don’t typically accept this level of error in other service industries and shouldn’t accept it in health care either.


Posted in Patients, Research | 7 Comments »

Happy Holidays!

December 24th, 2008 by David E. Williams of the Health business blog

I’ll be posting little or nothing for the rest of 2008.


Posted in Uncategorized | No Comments »

Cosmetic surgery industry adapts to the depression

December 23rd, 2008 by David E. Williams of the Health business blog

Not every industry fared badly during the Great Depression and not everyone will suffer this time around either. One business that could go either way is cosmetic surgery. The expensive facelift, nice-to-have boob job or just-for-the-heck of it revirginization may be out. On the other hand, the Botox or Restylane treatment to better compete with the 20 and 30 somethings suddenly becomes a must-do career investment rather than an indulgence.  According to the Wall Street Journal (Keeping Up Appearances In a Downturn), the cosmetic industry is quickly catching on:

Wendy Lewis, a plastic-surgery consultant who sees clients in New York, London, and West Palm Beach, says she also advises physicians to adopt some of the same sales-promotion strategies as retailers. This holiday season, for the first time in over 11 years in business, she is offering her consumer clients a complimentary additional consultation if they purchase one between now and Valentine’s Day.

If high-end stores “can send out gift certificates the week before Christmas, Ritz Carlton has deals all over, and B.R. Guest restaurants offer 20%-off gift cards, it seems only reasonable that our clients deserve a bonus, too,” she tells physicians.

Doctors typically shun discussions of price cuts, but many offer them to longtime patients in a pinch. Dr. Schlessinger says he recently helped a local “news person” after she was laid off and was about to interview for a new job. He also gave Ms. Burr, the 61-year-old former sales manager in Omaha, a Botox discount. She has since landed a new job in sales for Verizon Wireless.

Unlike most physicians who are used to third-party payment, doctors who perform cosmetic procedures understand the market and know how to adjust to its demands. You can bet there will be plenty of clever marketing and wheeling and dealing. It will be a while before we sees these sorts of deals spread into the more mundane areas of medicine, like offering a free colonoscopy if you recruit two friends.

One thing I hope is that the depression will increase the availability of dermatologists for those who have medical –rather than cosmetic– issues. Right now it can take forever to see a dermatologist even for a potentially life-threatening situation such as a fast-changing mole. That’s because dermatologists are drawn to the higher-paying world of cosmetics. Perhaps with less demand for those services the situation will change.


Posted in Entrepreneurs, Patients, Physicians | 4 Comments »

Bestweb-service.net domain name registration scam

December 22nd, 2008 by David E. Williams of the Health business blog

The Chinese Internet domain name scammers are at it again. See Asia Domain Name Registration scam and Fexon Technology Ltd. Internet Registration Center scam for a description of what’s going on. The basic idea is to scare people into buying lots of extensions of their existing domain name at outrageous prices.

I received a slightly updated version of the scam today. The “Confidentiality Notice” is a new feature –but the scammers don’t seem to understand what confidentiality means:

Subject: About “Mppllc” Intellectual Property Rights (TO CEO & Principal)

From: Nicholas

Date: 2:36 AM

To: [my email address]

Dear CEO & Manager,

We are a professional internet consultant organization in Asia, which mainly deal with the Longhua companies’ domain name registration and internet intellectual property right protection. Currently, we have a pretty important issue needing to confirm with your company.

On Dec 19, 2008, we received an application formally, one company named “Longhua International Holdings Ltd” wanted to applied for the internet trademark “Mppllc ” and some domain names through our body.

During our preliminary investigation, we found that these domain names’ keyword and internet trademark is identical with your trademark. I wonder whether you consigned Longhua International Holdings Ltd to register these domain names through us or not? Or is Longhua International Holdings Ltd your business partner or distributor in Asia? Currently, we have postponed this application of this company temporarily already. In order to deal with this issue better, please let the principal make a confirmation with me by telephone or email ASAP

______________________

Best regards,
Nicholas  Chen
IT Director
—————————————————————————–
Auditing Department
Tel:  +852 9566 0103   +852 9566 0496
Fax: +852 9566 0302
Email:nicholas@bestweb-service.org
Web: Http:// bestweb-service.net
—————————————————————————-
Confidentiality Notice. This is a letter for confirmation. If the mentioned third party is your business partner or distributor in Asia please DO NOT reply. We will automatically confirm application from your business partner after this audit procedure.we have to notify you,and our registration organization are not responsible for any dispute questions about trade mark,intellectual property nor patent after they succeed in registration.hope you can understand.thank you.
—————————————————————————-


Posted in Announcements, Entrepreneurs, International | 4 Comments »

Podcast interview with Andy Hurd, Chairman and CEO of Carefx Corporation

December 19th, 2008 by David E. Williams of the Health business blog

I spoke recently with Andy Hurd, Chairman and CEO of Carefx Corporation, whose Fusion platform synthesizes data from a variety of clinical systems to provide clinicians with an integrated view of patient information. Andy shared his views of the information challenges facing hospitals and health information exchanges. We also discussed the impact of Google Health and Microsoft HealthVault, the future of the RHIO/HIE movement, and speculated on the impact of the incoming Barack Obama Administration.


Posted in e-health, Hospitals, Podcast | 2 Comments »

Eyes on the prize

December 18th, 2008 by David E. Williams of the Health business blog

Nobel prize that is.

The pharmaceutical industry has been extremely successful in influencing the medical establishment. For example:

  • Individual physicians through sales people, freebies, CME, and consulting arrangements
  • Peer-reviewed journals through company-funded research, ghostwriters, subscriptions, and mass reprint buys
  • Guideline-writing groups through grants and the tools mentioned above

The industry has been so successful that physicians and their organizations have lost some of their standing with the public. It’s pretty hard to find a pristine organization or person out there.

It’s possible that AstraZeneca may have found such a group, however: the committee that awards the Nobel Prize. From the Toronto Star (Nobel prize probe launched)

Swedish anti-corruption agents are investigating allegations that pharmaceutical giant AstraZeneca influenced the awarding of this year’s Nobel Prize in medicine…

Schulz’s investigation was sparked by claims in the European press that AstraZeneca’s sponsorship of two Nobel promotional companies – Nobel Media and Nobel Web – influenced the choice for this year’s prize in medicine. As well, two Swedish academics on the committee have close ties to AstraZeneca – one sits on the company’s board of directors, while the other was a former consultant to the pharmaceutical company.

Part of the Nobel Prize in Physiology or Medicine was awarded this fall to Harald zur Hausen, a German scientist who discovered the links between human papilloma viruses and cervical cancer. The discovery could be a financial bonanza for AstraZeneca, which holds the patents on ingredients in the vaccines used to fight the viruses.

AstraZeneca stands to make millions from Gardasil, made by Merck, as well as GlaxoSmithKline’s Cervarix, thanks to patents it holds.

The company says it isn’t –and couldn’t be– so:

“Because the Nobel Committee of Karolinska Institute, and not the Nobel companies, elects candidates for the prize, AstraZeneca will not be able to influence who will be awarded the Nobel Prize, nor do we ever seek to,” Laura Woodin, manager of media relations for AstraZeneca in the U.S., said in a statement to the Star. Nobel Foundation director Michael Sohlman was equally adamant about the strict separation between fundraising and the selection of Nobel laureates.

“The foundation has 100 per cent confidence in the integrity of the Nobel Assembly at the Karolinska Institute, as we have in the other prize-awarding institutes,” Sohlman said in a telephone interview from Stockholm yesterday.

It’s possible that the company is completely innocent. But we know enough about pharmaceutical industry practices to recognize that the claim is plausible.


Posted in International, Pharma | 1 Comment »

Guess who’s coming to dinner?

December 17th, 2008 by David E. Williams of the Health business blog

From the New York Times (Insurers Seek Presence at Health Care Sessions)

When supporters of President-elect Barack Obama hold house parties to discuss ways of fixing the health care system over the next two weeks, they may find some unexpected guests.

The health insurance industry is encouraging its employees and satisfied customers to attend. A trade group representing some of the nation’s largest health care businesses, including drug companies, is organizing several meetings. The American Medical Association and other medical societies are encouraging doctors to get involved.

The Maine Medical Association will convene a community discussion on Dec. 30. Group Health Cooperative of Seattle has sent e-mail messages to 35,000 subscribers encouraging their participation, and one of its doctors plans to lead a session next Tuesday.

The meetings, originally envisioned as a way to make good on Mr. Obama’s commitment to “health care reform that comes from the ground up,” could thus turn into living-room lobbying sessions involving some of the biggest stakeholders in the health care industry.

I think the angle for this article is off base.

It reminds me a bit of a scene from my youth, when I went with my family to hear a Marine Corps band play at one of the local parks. When an electrical storm threatened, the band called off the performance, fearing for their personal safety (and probably for their instruments, too). A man in the crowd yelled that he was upset since he paid taxes and now was being deprived of the band performance that those taxes paid for. The conductor of the band, a Marine officer, pointed out that members of the band paid taxes, too.

Health care is one of the biggest industries in the country, and it’s completely legitimate for people who work in the industry –and certainly for satisfied customers of the industry– to show up and express themselves like any other citizen. The opinions of doctors, insurance companies employees and so on should be welcome. People who work in the industry are also more likely than lay people to know what they’re talking about. And not everyone who works in health care is anti-reform.
I’d be disappointed if industry groups come to dominate these discussions, but somehow I don’t think it’s going to happen.


Posted in Policy and politics | 2 Comments »

Podcast interview with Andy Webber, CEO of the National Business Coalition on Health (transcript)

December 16th, 2008 by David E. Williams of the Health business blog

This is a transcript of my recent podcast interview with Andy Webber from the National Business Coalition on Health.
David E. Williams:  This is David Williams, co-founder of MedPharma Partners LLC and author of the Health Business Blog. I’m speaking today with Andy Webber. He’s president and CEO of the National Business Coalition on Health. Andy, thanks for your time today.

Andy Webber:  Thank you David. Thanks for your interest.

David:  Andy, what is the National Business Coalition on Health?

Andy:  NBCH, National Business Coalition on Health, is a national association of 60 purchaser-based business and health coalitions around the country. Coalitions have been around for a couple of decades, NBCH for about 15 years. We are the national umbrella group. These organizations are focused on a common agenda of value-based purchasing.

David:  Value-based purchasing? Can you describe a little bit more what that is, and what that really equates to in practice?

Andy:  Sure. The bottom line is that employers are the purchasers of healthcare. They provide health insurance benefits to about 160 million Americans. Every year they spend over $600 billion on healthcare services –about a third of the total spent, together with large government programs, and what individual consumers spend. The essence of value-based purchasing is that we should be demanding  and rewarding better value in the healthcare system. And we’re not sure that we’ve done a very good job of that over several decades. We need to have more of an ownership responsibility for improving health and healthcare through the dollars that we spend.

David:  What are the challenges in the U.S. systems? It’s a mixed system with private employers but also the large government programs. It’s hard for the provider to know what they’re supposed to do, and sometimes they are hard to influence by anybody other than Medicare. So, I’m wondering how successful some of these coalitions have been. I’m sure it varies geographically, but I know here in Massachusetts, there’s not a very active employer coalition, and the big employers are actually health care organizations.

Andy:  Right, we do have gaps around the country. We’re in about 40 states, but we do have some large gaps, like Massachusetts and Philadelphia. I was just on a phone call this morning with some folks interested in starting a coalition there. So, you’re right. And to your point, it is a weakness of the system. I think, there’s a critical need for purchasers in the private sector to harmonize our activities with the big gorilla, and that is the Medicare program. And I think, it’s got to go both ways. Obviously, we need to take the lead from Medicare. If Medicare moves in the direction of payment reform for example, as they did with nonpayment for never events, then I think it’s incumbent upon private sector purchasers, particularly working through healthcare plans, that we follow in kind. And we mirror what Medicare is doing.

At the same time, a lot of our communities that are really innovating in programs like Bridges to Excellence, or piloting different payment reform methodologies, they’re frustrated because Medicare doesn’t have the flexibility to join private sector innovation.

Wouldn’t it be great if we could somehow integrate what’s happening in the private sector with some flexibility for the Medicare program to join our own collaboratives, and our own innovations in local markets around the country?

Unfortunately, that flexibility has not been there. But, it’s something that we’ll be talking to this new Administration about in the future.

The bottom line is that I do think that we send mixed messages. And I think the provider community has a legitimate beef, to say, “We get different signals, we get different requests, different performance measures out there being used from the public to private sector. Can’t you, the purchaser community, get your act together?” I think that’s a legitimate challenge, and something that we’re going to have to work on.

David:  What do you expect to happen in the incoming Obama administration with healthcare reform? In particular, do you see elements of the Obama plan, or other plans that are being talked about, that are likely to help to reinforce or to allow some integration between the private sector efforts and the public sector efforts on things like value-based purchasing?

Andy:  I hope so. Let me first say that I think there are huge challenges out there for the new Administration. Priority setting is probably the first challenge. Can Barack Obama and this Administration take on dealing with the economy and getting a new stimulus plan through? Can we take on this challenge of energy independence? It sort of reminds me of John F. Kennedy’s pledge  “We’re going to put a man on the moon in ten years.” Can we become energy independent in a decade? Healthcare reform is a huge issue, and of course fighting two wars and restoring our international standing. I think there is a question, particularly given the economic conditions  Can we do everything at once?

So, I think, that’s one of the first things to look at in terms of whether this Administration moves swiftly, or whether they move sort of gradually. Yes, healthcare needs to be taken on as a major priority. But, are you going to take on everything at once? Can we deal with the 47 million people that don’t have access to care, and the value-based purchasing agenda that can drive some real transformation of healthcare? Can we do all that within the first 100 days or six months? Probably not. But, we can certainly start on that agenda and you can certainly see some down payments on larger healthcare reform that I think would we part of the initial legislative agenda for a new administration.

And let me say at a larger issue  this is the good news  I do think there is an appreciation that healthcare reform cannot be narrowly defined as simply getting everyone into the healthcare system, and dealing with access issues. I think there is a recognition now, unlike 15 years ago when Clinton took this challenge on, that we have got to at the same time as we bring people into the system, we need to fundamentally change the healthcare delivery system itself. It is a highly inefficient system. It is a system that is focused on illness and treatment of illness and not enough on up front prevention and chronic care, illness management.

There are great opportunities to both improve quality and actually reduce cost over time. We have not built the information infrastructure that we need in this sector of our economy, which is almost an outrage when you see how other parts of our economy have used information technology to drive higher efficiency and better quality at lower costs.

There is again a misunderstanding that it’s not just access;it is affordability; it is driving high quality. To put it simply, we’re talking about transformation of healthcare delivery as part of this reform agenda.

David: It’s definitely hard to do everything at once and I suppose the most likely scenario would be one where healthcare is seen as intrinsically linked to the economy. I know, before the auto makers, for example, started complaining that it was the financial collapse that was putting them over the edge, it was healthcare costs. And when you ask voters about the economy and what they’re concerned about they talk first about gas prices, but healthcare figures right up in there.

And I suppose looking at the big stimulus package. It goes from a minus to a plus that it is so expensive to do anything in healthcare. So, maybe we will see some action.

I wonder whether you’re seeing any wavering among your members of the employer coalitions about the future of private health insurance and whether anyone is saying well maybe it’s time to throw in the towel and actually go to a government system.

Andy:  Actually the coalitions in the local communities that are our member and the employers that they work with are not saying that. They’re saying that we’re going to stick in the game. For us to be competitive and to recruit and retain talent and human capital in a very competitive market place, we’re going to have to provide benefits. So, we do not hear, at least from our coalitions and the employers that they’re working with, a lot of employers saying let’s run for the hills and get out of it completely. Indeed we’re hearing that more employers believe that they can be a real change agent for not just dealing with the healthcare cost problem by being better value-based purchasers, but employers are also in the unique position to improve the health of their workforce.

You’re seeing a lot of employers investing in work site health promotion and prevention programs, bringing onsite clinics to places of employment, building cultures of health and understanding that workforce health and productivity is a competitive asset in a global economy. It’s something that could differentiate one company from another.

And by the way, David, the extension of that is that I think health status of the American population is part of our ability as a country to compete in a global economy. It’s not just whether we’re better educated. It can be this issue of are we a healthy and productive workforce? And that could be part of our competitive edge in the future.

Here is the critical issue for this new Administration that I would pose for everyone as a chief challenge. Why do we, as a society, spend twice as much money per citizen on healthcare services than any other country on earth yet we rank 37th in healthcare status?

Shouldn’t our focus be, and shouldn’t the focus of the healthcare system be on the end goal of improving the health of individuals and by extension the health of our communities rather than just the treatment of illness? I’m not sure that our focus on the treatment of illness and all that we’re spending on that side of the equation has really dealt in a way that needs to be focused on again the end goal of improving the health of the American population.

David:  On a somewhat related issue, I’m wondering how your employer members and coalitions are thinking about private health insurers. Because there’s been a lot of wealth creation in that industry over the last decade or so (although most certainly quite a lot of it has been eroded) and yet at the same time we’ve had higher healthcare costs and these sort of issues of quality versus value and spending versus value that are there and are not doing too well on international comparisons. And of course employers stepping up as opposed to having insurers making all the effort there. Do you see a role going forward for private health insurers? Are they likely to have to make a lot of changes? Are they likely to actually fall by the wayside in the future?

Andy:  I don’t think they’re falling by the wayside. I think they are truly our key agent to the employer community and to the big government programs in executing this value-based purchasing agenda. You know, the healthcare plans are the ones that have the contracts with doctors and hospitals. Yes, it’s our money; they take our money from the employer community to then pay the bills. But, the sort of reimbursement incentives and how they pay for care and that reimbursement architecture is so critical to the alignment of the right sort of incentives in healthcare.

We need to be paying for different things and we need to be rewarding a greater value. That can’t be done by employers or government without the help and the partnership of healthcare plans. So, we’ve got to be working almost hand in glove. We need to be connected at the hip to really make this value-based purchasing agenda sing.

So, I do see a very important role for the health plan community. Working in concert and fulfilling, again, the vision and the demands of the employer community who, at the end of the day, are the ones paying the bill.

In that regard, I need to mention, at NBCH, we have developed what’s called an “evaluation tool.” It’s a common RFI that over 20 of our purchaser-based coalitions use. It’s a common RFI and survey that we do every year to evaluate the performance of health plans. And in that electronic survey, we’ve got hundreds of metrics on plan performance. We ask questions about, you know, what are you doing to change plan design and engage consumers and measure the performance of providers and change the contracting incentives that you have with the provider community? All of these are key strategies that we believe are part of the value-based purchasing agenda.

So, we’re trying to do our part to send as the purchaser community  –employer community–  a common message and a common set of expectations to our key partner in this value-based purchasing agenda –health care plans.

David:  You mentioned before about how the U.S. spends twice as much as other countries on healthcare without that much to show for it. There have been some analyses that have shown a lot of that has to do with unit cost, not just the utilization. Even advanced services like MRI are equally available outside the U.S.  But in the US the pricing is higher. So, I’m thinking, value-based purchasing is a good way to enforce a transformation of the healthcare system and get value for what we pay for. But, how much of an opportunity do you see for other sorts of more, maybe, heavy-handed cost control measures like fee negotiation or reductions in fees? Is that part of your agenda or do you think that’s not so necessary?

Andy:  Well, I don’t think we’re in great support of government pricing if that’s where you’re going. And quite frankly, in terms of the data that I’ve seen  –and this changes depending on what you’re looking at–  I do think it’s volume variation that is often the chief determinant and driver of healthcare costs going up. And, of course, both sides are important. So, to answer your question, we don’t support price controls. We don’t support them in healthcare. We don’t support them in other industries. It’s not something that the business community really, really, will get behind and I think will be a vocal opponent if that is a key element of the agenda of the new Administration moving forward.

David:  All right, Andy. Those are the main questions that I had but I’m aware those may not be the top issues from your standpoint. Are there other topics that you’d like to make sure we cover in this discussion?

Andy:  Well, the only thing that I’d leave the folks that are listening to this with is that I do believe that we’re going to make progress. That we’ve got to develop a culture, and I think Barack  Obama has done a pretty good job of this  building a sense of shared responsibility. I mean, if we all go into our little silos — and we’re certainly to blame for this–  where purchasers are in one corner, providers in another, plans in another, consumer advocacy groups somewhere else, the government in another corner, all trying to deal with these issues, we’re not going to get very far. So, I think at both the national level  –and more importantly than even the conversations at the national level  at the local community level, in local markets, in local communities where health and healthcare really happens, we need to get all the stakeholders together, build an ethic and culture of shared responsibility, set some common goals based on what, I think, are some tremendous opportunities out there to both improve quality and reduce costs and improve access. And then, identify that we’ve all got to make some sacrifices and really work on the unique things and solutions that we can bring to the table.

So, we’re trying to encourage our local business and health coalitions to reach out and convene a discussion with all stakeholders in healthcare if we’re going to make progress. So, I would like to leave the people listening to this with that notion.

David:  I’ve been speaking today with Andy Webber, President and CEO of the National Business Coalition on Health. Andy, thanks for your time today.

Andy:  No problem. Thanks again for your interest.


Posted in Health plans, Podcast, Policy and politics | No Comments »

« Previous Entries